Circulating MrgD in Pulmonary Hypertension

Pulmonary Hypertension Clinical Trial

Official title:

Circulating MrgD Change in Patients With Pulmonary Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06365372
• Other study ID #: MrgD and PAH
• Status: Recruiting
• Start date: April 10, 2024
• Est. completion date: June 1, 2024

Study information

• Verified date: April 2024
• Source: Qilu Hospital of Shandong University
• Contact: Panpan Hao, MD
• Phone: 8618560086593
• Email: panda.how[@]sdu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of the study is to observe the change of the circulating MrgD level in patients with pulmonary hypertension compared with subjects without pulmonary hypertension.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: June 1, 2024
• Est. primary completion date: May 10, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria for patients with pulmonary hypertension:

1. Male or female aged =18 years

2. Right heart catheterisation to check the mean pulmonary artery pressure (mPAP) =25mmHg

3. The patient is willing and able to provide written informed consent.

Exclusion criteria for patients with pulmonary hypertension:

1. Age less than 18 years old

2. Mean pulmonary artery pressure (mPAP) <25mmHg

3. Unable to provide informed written consent for participation in the study

4. Renal insufficiency

5. Liver insufficiency

6. Malignant tumor

7. Active infection

8. Pregnancy

Inclusion criteria for control subjects:

1. Male or female aged =18 years

2. No evidence of pulmonary hypertension on echocardiography or mean pulmonary artery pressure (mPAP) < 25 mmHg on right heart catheterization, and no evidence of clinically relevant heart disease

3. No evidence of clinically relevant pulmonary disease

Exclusion criteria for control subjects:

1. Age less than 18 years old

2. Mean pulmonary artery pressure (mPAP) =25mmHg

3. Unable to provide informed written consent for participation in the study

4. Symptoms of heart failure or clinically relevant lung disease

5. Renal insufficiency

6. Liver insufficiency

7. Malignant tumor

8. Active infection

9. Pregnancy

Related Conditions & MeSH terms

• Hypertension
• Hypertension, Pulmonary
• Pulmonary Hypertension

Intervention

Diagnostic Test:
• Western blot
Samples were measured by Western blot using a solution for the separation of lymphocytes from peripheral blood.

Locations

Country	Name	City	State
China	Qilu Hospital of Shandong University	Jinan	Shandong

Sponsors (1)

Lead Sponsor	Collaborator
Qilu Hospital of Shandong University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Circulating MrgD level		From 2022 to 2024